Contract testing services for drug development using PXB humanized-liver mice
First written in FY2016. 23 of 25 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Transition to a structure comprising 2 consolidated subsidiariesAnnual report
「The Group consists of the Company and 2 consolidated subsidiaries, and its principal business is contract testing services for drug development using PXB mice (chimeric mice with human hepatocytes).」
Following the completion of the liquidation of KMT Hepatech,Inc., the Group comprises 2 consolidated subsidiaries, while continuing to operate a business whose principal activity is contract testing services using PXB mice. - FY2026-H1RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the interim consolidated accounting period. There were also no changes among its principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2024-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the third quarter of the current consolidated cumulative period. There were also no changes among the principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies). There were also no changes among its principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2023RestatedAnnual report
「The Group consists of the Company and 3 consolidated subsidiaries, and its principal business is contract testing services for drug development using PXB mice (chimeric mice with human hepatocytes).」
Reconfirms the structure comprising 3 consolidated subsidiaries and a single segment whose principal business is contract testing services using PXB mice. - FY2023-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the third quarter of the current consolidated cumulative period. There were also no changes among the principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies). There were also no changes among its principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2023-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the first quarter of the current consolidated cumulative period. There were also no changes among the principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2022-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the first quarter of the current consolidated cumulative period. There were also no changes among the principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies). There were also no changes among its principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on the PXB mouse business, or to its principal affiliates. - FY2021-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the first quarter of the current consolidated cumulative period. There were also no changes among the principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2020RestatedAnnual report
「The Group consists of the Company and 3 consolidated subsidiaries, and its principal business is contract testing services for drug development using PXB mice (chimeric mice with human hepatocytes).」
Reconfirms the structure comprising 3 consolidated subsidiaries and a single segment whose principal business is contract testing services using PXB mice. - FY2020-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the third quarter of the current consolidated cumulative period. There were also no changes among the principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its principal affiliates. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies). There were also no changes among its principal affiliated companies.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice, or to its affiliates. - FY2019RestatedAnnual report
「The Group consists of the Company and 3 consolidated subsidiaries, and its principal business is contract testing services for drug development using PXB mice (chimeric mice with human hepatocytes).」
Reconfirms the structure comprising 3 consolidated subsidiaries and a single segment whose principal business is contract testing services using PXB mice. - FY2019-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses operated by the Group (the Company and its affiliated companies) during the cumulative third quarter of the fiscal year under review.」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice. - FY2018RestatedAnnual report
「The Group consists of the Company and 3 consolidated subsidiaries, and its principal business is contract testing services for drug development using PXB mice (chimeric mice with human hepatocytes).」
The Group now comprises 3 consolidated subsidiaries, including KMT Hepatech,Inc., while maintaining a single-segment structure whose principal business is contract testing services using PXB mice. - FY2018-Q3RestatedAnnual report
「During the first 9 months of the fiscal year, there were no significant changes to the business conducted by the Group (the Company and its affiliates). In the third quarter, KMT Hepatech,Inc. was acquired and made a wholly owned subsidiary, and was therefore included in the scope of consolidation.」
Although there were no significant changes to the core business, the scope of consolidation changed following the acquisition of KMT Hepatech,Inc. as a wholly owned subsidiary. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the business activities conducted by our Group (the Company and its affiliated companies).」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice. - FY2018-Q1RestatedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the business activities conducted by our Group (the Company and its affiliated companies).」
Reconfirms that there have been no significant changes to the business, which centers on contract testing services using PXB mice. - FY2017RestatedAnnual report
「The Group consists of the Company and 2 consolidated subsidiaries, and its principal business is contract testing services for drug development using PXB mice (chimeric mice with human hepatocytes).」
Reconfirms that the business centers on the PXB mouse business, which is the sole segment. - FY2017-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses operated by the Group (the Company and its affiliated companies) during the cumulative third quarter of the fiscal year under review.」
Reconfirms that there have been no significant changes to the business, which centers on the PXB mouse business. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the business activities conducted by our Group (the Company and its affiliated companies).」
Reiterates that there have been no significant changes to the business, which centers on the PXB mouse business. - FY2017-Q1RestatedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the business activities conducted by our Group (the Company and its affiliated companies).」
States that there have been no significant changes to the business, which centers on contract testing services using PXB mice. - FY2016First statedAnnual report
「The Group consists of the Company and 2 consolidated subsidiaries, and its principal business is contract testing services for drug development using PXB mice (chimeric mice with human hepatocytes).」
The PXB mouse business is described as the core business and the sole reportable segment.